Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas

Temozolomide (TMZ) is a chemotherapeutic agent that has been the first-line standard of care for the aggressive brain cancer glioblastoma (GBM) since 2005. Although initially beneficial, TMZ resistance is universal and second-line interventions are an unmet clinical need. Here, we took advantage of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiek, Deanna M., Erdogdu, Beril, Razaghi, Roham, Jin, Lu, Sadowski, Norah, Alamillo-Ferrer, Carla, Hogg, J. Robert, Haddad, Bassem R., Drewry, David H., Wells, Carrow I., Pickett, Julie E., Song, Xiao, Goenka, Anshika, Hu, Bo, Goldlust, Samuel A., Zuercher, William J., Pertea, Mihaela, Timp, Winston, Cheng, Shi-Yuan, Riggins, Rebecca B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216507/
https://www.ncbi.nlm.nih.gov/pubmed/35731869
http://dx.doi.org/10.1126/sciadv.abn3471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216507/
https://www.ncbi.nlm.nih.gov/pubmed/35731869
http://dx.doi.org/10.1126/sciadv.abn3471

Ejemplares similares